Skip to main content
. 2021 May 8;16(5):705–716. doi: 10.2215/CJN.16751020

Figure 1.

Figure 1.

Patient flow in the CKD subgroup of the BETonMACE trial of apabetalone for reduction of adverse cardiovascular events in patients with acute coronary syndrome and type 2 diabetes. 1Discontinuation due to patient preference. LFTs, liver function tests; MACE, major adverse cardiovascular events.